Clinical Trial Update: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Brexucabtagene Autoleucel (KTE-X19) in relapsed/refractory mantle cell lymphoma (Cohort 3) indicates the study status is completed; det…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Brexucabtagene Autoleucel (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED